NasdaqGS:ABCLLife Sciences
AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate
AbCellera Biologics jumped 10.3% to US$6.53 today, a sharp move for a stock that came into the print with a mixed recent run, up over the past week but down over the past month. The market is reacting to one thing above all else: the company is leaning hard into a high cash burn and deeper quarterly loss to fund its antibody pipeline, backed by a reported US$567 million cash pile and more than US$675 million of available liquidity.
The question now is whether that liquidity cushion really...